(function(){
			var content_array=[" \n<p><b>About TransCelerate BioPharma Inc.<br \/><\/b>TransCelerate BioPharma Inc. is a non-profit organization dedicated to improving the health of people around the world by accelerating and simplifying the research and development (R&amp;D) of innovative new therapies. The organizations' mission is to collaborate across the global biopharmaceutical R&amp;D community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines. TransCelerate evolved from discussions at various forums for executive R&amp;D leadership to debate current issues facing the industry, and examine solutions for addressing agreed-upon common challenges. The founding member companies are AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson &amp; Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined since the inception of TransCelerate include Allergan, Inc., Astellas Pharma Inc., Biogen Idec, Cubist Pharmaceuticals, EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, <span class=\"xn-location\">Germany<\/span>), Forest Research Institute (a subsidiary of Forest Laboratories, Inc.), Medgenics, Inc., Shionogi &amp; Co., Ltd. and UCB. <\/p> \n<p>Membership in TransCelerate is open to pharmaceutical and biotechnology companies with Research &amp; Development operations. Executive offices are located in <span class=\"xn-location\">Philadelphia, PA.<\/span> For more information, please visit <a href=\"http:\/\/www.transceleratebiopharmainc.com\/\" target=\"_blank\" rel=\"nofollow\">http:\/\/www.transceleratebiopharmainc.com<\/a>.&nbsp;&nbsp;&nbsp;<\/p> \n<p><b>About Cognizant's Healthcare and Life Sciences Practice<br \/><\/b>Cognizant's Healthcare and Life Sciences practice is committed to helping change millions of lives for the better by partnering with clients to build solutions to healthcare challenges, continually improve the way they do business, set the pace in clinical development, strengthen their regulatory infrastructure, and increase competitiveness. Consistently ranked among the top 10 on the Healthcare Informatics Top 100, Cognizant serves 27 of the top 30 global pharmaceutical companies, 15 of the top 20 health plans in the U.S., 5 of the top 6 pharmacy benefit management companies in the U.S., 9 of the top 10 biotech companies, and 12 of the top 20 medical device companies. With a large team of dedicated professionals including doctors, pharmacologists, physicians, biomedical engineers, pharmacists, biostatisticians, medical writers, and GxP consultants, the practice provides domain-aligned consulting, IT, business process and analytics solutions globally.<\/p> \n<p><b>About Cognizant<br \/><\/b>Cognizant (NASDAQ: CTSH) is a leading provider of information technology, consulting, and business process outsourcing services, dedicated to helping the world's leading companies build stronger businesses. Headquartered in <span class=\"xn-location\">Teaneck, New Jersey<\/span> (U.S.), Cognizant combines a passion for client satisfaction, technology innovation, deep industry and business process expertise, and a global, collaborative workforce that embodies the future of work. With over 75 development and delivery centers worldwide and approximately 178,600 employees as of <span class=\"xn-chron\">March 31, 2014<\/span>, Cognizant is a member of the NASDAQ-100, the S&amp;P 500, the Forbes Global 2000, and the Fortune 500 and is ranked among the top performing and fastest growing companies in the world. Visit us online at <a href=\"http:\/\/www.cognizant.com\" rel=\"nofollow\">www.cognizant.com<\/a> or follow us on Twitter: Cognizant.&nbsp;&nbsp;<\/p> \n<p><b>Forward-Looking Statements<br \/><\/b><i>This press release includes statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those expressed or implied include general economic conditions and the factors discussed in our most recent Form 10-K and other filings with the Securities and Exchange Commission. Cognizant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.<\/i><\/p> \n<p><br \/><\/p>"];
			$("#dvExtra").html(content_array[0]);})();